ABVC BioPharma (NASDAQ:ABVC – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.37, Zacks reports.
ABVC BioPharma Price Performance
ABVC stock opened at $0.88 on Friday. The firm has a market cap of $23.36 million, a PE ratio of -3.01 and a beta of 0.57. ABVC BioPharma has a 12 month low of $0.88 and a 12 month high of $3.40. The firm has a 50 day simple moving average of $1.31 and a 200 day simple moving average of $1.34.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings upgraded ABVC BioPharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, ABVC BioPharma currently has a consensus rating of “Sell”.
Institutional Trading of ABVC BioPharma
Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in ABVC BioPharma by 7.7% in the fourth quarter. Geode Capital Management LLC now owns 202,365 shares of the company’s stock valued at $431,000 after purchasing an additional 14,553 shares in the last quarter. Millennium Management LLC bought a new stake in ABVC BioPharma during the third quarter valued at about $60,000. Finally, Citadel Advisors LLC bought a new stake in ABVC BioPharma during the 3rd quarter valued at approximately $48,000. 11.38% of the stock is owned by institutional investors and hedge funds.
About ABVC BioPharma
ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.
The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.
See Also
- Five stocks we like better than ABVC BioPharma
- Cerebras Sells Off After Earnings: Is This a Market Disconnection?
- Is Lockheed Martin Gearing Up to Lead Defense Stocks?
- Inside Teledyne’s Bold Bet on the Future of Medical Imaging
- Why Are Analysts Freaking Out About Apple’s All-Glass iPhone?
Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
